Vera Pins Hopes On Per-Protocol Analysis To Revive Phase II IgAN Asset
As Firm Reprioritizes Resources
Executive Summary
The US firm is shifting its focus to IgAN after a promising new prespecified analysis of its Phase II trial of atacicept lifted hopes for the product’s prospects as compared with a key rival candidate.
You may also be interested in...
Finance Watch: Structure Launches Third And Largest US Biopharma IPO Of 2023
Public Company Edition: Structure Therapeutics’ upsized initial public offering raises $161.1m, surpassing proposed terms for up to $134.3m. Also, Pliant capitalizes on good data with a $287.5m follow-on offering, while Magenta seeks strategic alternatives and Instil reveals more job cuts.
EIP And Diffusion Combine To Form CNS Firm With Dementia Focus
The US biotechs are joining forces to form a new, listed company with sufficient cash to advance EIP’s potentially disease-modifying drug candidate through Phase II development in dementia with Lewy bodies, which presents a high unmet need.
Executives On The Move: Applied Molecular Transport, Alimera Sciences and More
Recent executive changes in the industry include C-suite changes at Exicure and Applied Molecular Transport. Meanwhile, new directors were appointed at Immunotech Biopharm and Alimera Sciences.